-+ 0.00%
-+ 0.00%
-+ 0.00%

TScan Therapeutics To Present New Research On T Cell Therapies At ACR Convergence 2025 In Chicago

Benzinga·09/17/2025 11:03:34
Listen to the news

TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of two abstracts, one as an oral presentation and another as a poster presentation, at the upcoming American College of Rheumatology (ACR) Convergence 2025 being held October 24 – 29 in Chicago, IL.